Barbara I Gulanski1, Clare A Flannery2, Patricia R Peter1, Cheryl A Leone3, Nina S Stachenfeld2,3. 1. Department of Medicine, Section of Endocrinology, Yale School of Medicine, New Haven, CT, USA. 2. Yale Department of Obstetrics, Gynecology and Reproductive Sciences. and Gynecology, Yale School of Medicine, New Haven, CT, USA. 3. The John B. Pierce Laboratory, New Haven, CT, USA.
Abstract
CONTEXT: Transgender men (TGM) are persons assigned female gender at birth with a male gender identity and are routinely treated with testosterone. Androgen excess is associated with endothelial dysfunction among cisgender females (CGF) and is an early sign of atherosclerosis and hypertension. OBJECTIVE: To determine the effect of testosterone treatment on endothelial function in TGM. SETTING: The John B. Pierce Laboratory and Yale School of Medicine. SUBJECTS: Eleven TGM (age 27 ± 5 years; BMI 24.4 ± 3.7 kg/m2 ) receiving testosterone (T) and 20 CGF (28 ± 5 years; BMI 26.0 ± 5.1 kg/m2 ) during the early follicular phase of their menstrual cycle. DESIGN AND OUTCOME MEASURES: We evaluated brachial vasodilatory responses following stimuli designed to elicit shear stress using 5-minute occlusion to determine endothelial function (flow-mediated vasodilation, FMD). RESULTS: Total T was greater in the TGM compared to CGF (484.6 ± 122.5 vs 1.5 ± 0.7 ng/dL), as was free T (83.9 ± 32.4 vs 1.9 ± 0.8 pg/dL). FMD was markedly lower in the TGM (4.5 ± 2.7%) compared to the CGF (8.1 ± 2.9%, P = .002) indicating significantly diminished endothelial function in TGM. CONCLUSIONS: We have shown for the first time that in TGM the androgen-dominant hormonal milieu was associated with impaired endothelial function. Endothelial dysfunction precedes clinically detectable atherosclerotic plaque in the coronary arteries, so is an important marker for clinical cardiovascular risk. Therefore, attention to cardiovascular risk factors should be integral to the care of transgender men.
CONTEXT: Transgender men (TGM) are persons assigned female gender at birth with a male gender identity and are routinely treated with testosterone. Androgen excess is associated with endothelial dysfunction among cisgender females (CGF) and is an early sign of atherosclerosis and hypertension. OBJECTIVE: To determine the effect of testosterone treatment on endothelial function in TGM. SETTING: The John B. Pierce Laboratory and Yale School of Medicine. SUBJECTS: Eleven TGM (age 27 ± 5 years; BMI 24.4 ± 3.7 kg/m2 ) receiving testosterone (T) and 20 CGF (28 ± 5 years; BMI 26.0 ± 5.1 kg/m2 ) during the early follicular phase of their menstrual cycle. DESIGN AND OUTCOME MEASURES: We evaluated brachial vasodilatory responses following stimuli designed to elicit shear stress using 5-minute occlusion to determine endothelial function (flow-mediated vasodilation, FMD). RESULTS: Total T was greater in the TGM compared to CGF (484.6 ± 122.5 vs 1.5 ± 0.7 ng/dL), as was free T (83.9 ± 32.4 vs 1.9 ± 0.8 pg/dL). FMD was markedly lower in the TGM (4.5 ± 2.7%) compared to the CGF (8.1 ± 2.9%, P = .002) indicating significantly diminished endothelial function in TGM. CONCLUSIONS: We have shown for the first time that in TGM the androgen-dominant hormonal milieu was associated with impaired endothelial function. Endothelial dysfunction precedes clinically detectable atherosclerotic plaque in the coronary arteries, so is an important marker for clinical cardiovascular risk. Therefore, attention to cardiovascular risk factors should be integral to the care of transgender men.
Authors: Carl G Streed; Omar Harfouch; Francoise Marvel; Roger S Blumenthal; Seth S Martin; Monica Mukherjee Journal: Ann Intern Med Date: 2017-07-25 Impact factor: 25.391
Authors: Wylie C Hembree; Peggy T Cohen-Kettenis; Louis Gooren; Sabine E Hannema; Walter J Meyer; M Hassan Murad; Stephen M Rosenthal; Joshua D Safer; Vin Tangpricha; Guy G T'Sjoen Journal: J Clin Endocrinol Metab Date: 2017-11-01 Impact factor: 5.958
Authors: Elisabeth A Lambert; Helena Teede; Carolina Ika Sari; Eveline Jona; Soulmaz Shorakae; Kiri Woodington; Robyn Hemmes; Nina Eikelis; Nora E Straznicky; Barbora De Courten; John B Dixon; Markus P Schlaich; Gavin W Lambert Journal: Clin Endocrinol (Oxf) Date: 2015-05-13 Impact factor: 3.478
Authors: Jolanda M H Elbers; Erik J Giltay; Tom Teerlink; Peter G Scheffer; Henk Asscheman; Jacob C Seidell; Louis J G Gooren Journal: Clin Endocrinol (Oxf) Date: 2003-05 Impact factor: 3.478
Authors: Shehzad Basaria; S Mitchell Harman; Thomas G Travison; Howard Hodis; Panayiotis Tsitouras; Matthew Budoff; Karol M Pencina; Joseph Vita; Connie Dzekov; Norman A Mazer; Andrea D Coviello; Philip E Knapp; Kathleen Hally; Emma Pinjic; Mingzhu Yan; Thomas W Storer; Shalender Bhasin Journal: JAMA Date: 2015-08-11 Impact factor: 56.272
Authors: Nicolas Herrera-Zelada; Ursula Zuñiga-Cuevas; Andres Ramirez-Reyes; Sergio Lavandero; Jaime A Riquelme Journal: Front Pharmacol Date: 2021-02-02 Impact factor: 5.810
Authors: Carl G Streed; Lauren B Beach; Billy A Caceres; Nadia L Dowshen; Kerrie L Moreau; Monica Mukherjee; Tonia Poteat; Asa Radix; Sari L Reisner; Vineeta Singh Journal: Circulation Date: 2021-07-08 Impact factor: 39.918
Authors: Baris Gencer; Marco Bonomi; Maria Pia Adorni; Cesare R Sirtori; François Mach; Massimiliano Ruscica Journal: Rev Endocr Metab Disord Date: 2021-02-22 Impact factor: 6.514